In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Nanobiotix's reported revenue is lumpy and partner-linked, swinging from $32.9M in 2023Q4 to negative $16.5M in 2024Q4 and $5.6M in 2026Q2, which suggests top-line results depend on irregular milestone recognition rather than a stable commercial run-rate.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Sep 29, 2026 | -$0.80-64.7% vs -$0.48 | $6M+268.9% vs $2M |
Q2 2026 Mar 31, 2026 | -$0.46-250.7% vs $0.30 | $4M-93.2% vs $52M |
Q4 2025 Sep 30, 2025 | -$0.13+45.9% vs -$0.25 | $31M+31.2% vs $24M |
Q2 2025 Apr 2, 2025 | -$1.01-63.5% vs -$0.62 | $22M-709.2% vs $4M |
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acceptable safety profile and early signals of efficacy 41.7% (10/24) overall response rate (ORR) per RECIST 1.1, including 4 complete responses 75% (18/24) disease control rate (DCR) 17.8 months median Overall Survival Exploratory analysis in a subset of patients (n=8) identified IL-1β, a cytokine linked to treatment-induced anti-tumor immunity, as the most increased plasma cytokine after treatment Investigators concluded that these preliminary findings warrant further evaluation in randomized clinical trials for patients with primary cutaneous melanoma naïve or refractory to anti-PD-1 Data presented at the 2026 Congress of the European Society for Medical Oncology PARIS and CAMBRIDGE, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updated results from patients with anti-PD-1-resistant advanced primary cutaneous melanoma treated in the ongoing Phase 1 Study 1100.
Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report)'s stock price gapped down before the market opened on Thursday. The stock had previously closed at $31.16, but opened at $29.99. Nanobiotix shares last traded at $29.8790, with a volume of 9,803 shares traded. Wall Street Analysts Forecast Growth Several equities analysts have issued reports
Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report) saw an uptick in trading volume on Wednesday. 90,160 shares changed hands during trading, an increase of 1% from the previous session's volume of 88,938 shares. The stock last traded at $32.0210 and had previously closed at $31.50. Analysts Set New Price Targets NBTX has
Benchmark NBTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Nanobiotix S.A. (NBTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $27.45 | $1.39B | -49.91 | 512.28% | -80.83% | — | — | |
| $11.14 | $1.29B | -10.69 | 8.28% | -16.78% | -35.81% | — | |
| $2.44 | $7.32M | -0.49 | -12.34% | -4.41% | -36.6% | — | |
| $10.16 | $424.63M | -5.45 | 56.89% | -204.19% | -186.15% | — | |
| $3.00 | $1.08M | -0.04 | -67.7% | -7423.86% | -557.89% | — | |
| $58.01 | $2.83B | -12.49 | — | — | -1522.54% | — |
Nanobiotix S.A. (NBTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when NBTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Nanobiotix S.A. (NBTX) stock FAQ — growth, dividends, profitability & financials explained
Nanobiotix S.A. (NBTX) reported $29.6M in revenue in fiscal year 2025. That is 2079% more than the $1.4M of fiscal year 2011.
Nanobiotix S.A. (NBTX) grew revenue by 512.3% in fiscal year 2025, compared with the prior fiscal year.
No. Nanobiotix S.A. (NBTX) reported a net loss of $24.0M in fiscal year 2025.
Nanobiotix S.A. (NBTX) had negative free cash flow of $34.0M in fiscal year 2025.